Karen M. McGinn

Statistics

Publications

Citations

374

H-Index

Active since

2012

Affiliations

Center for Drug Evaluation and Research(Current)

Karen M. McGinn is an author at Center for Drug Evaluation and Research specializing in immunotherapy, response assessment, and hematologic malignancy therapy.

Publications per year

2012–2015

Publications

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 209 citations

Medicine, Oncology, Pharmacology +17

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun et al. · Clinical Cancer Research · 2015 · 165 citations

Medicine, Oncology, Pharmacology +17

1–2 of 2